These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22169248)

  • 1. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
    Javitt DC; Buchanan RW; Keefe RS; Kern R; McMahon RP; Green MF; Lieberman J; Goff DC; Csernansky JG; McEvoy JP; Jarskog F; Seidman LJ; Gold JM; Kimhy D; Nolan KS; Barch DS; Ball MP; Robinson J; Marder SR
    Schizophr Res; 2012 Apr; 136(1-3):25-31. PubMed ID: 22169248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia.
    Kumar S; Mulsant BH; Tsoutsoulas C; Ghazala Z; Voineskos AN; Bowie CR; Rajji TK
    Int J Geriatr Psychiatry; 2016 Oct; 31(10):1116-23. PubMed ID: 27428251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.
    Jarskog LF; Dong Z; Kangarlu A; Colibazzi T; Girgis RR; Kegeles LS; Barch DM; Buchanan RW; Csernansky JG; Goff DC; Harms MP; Javitt DC; Keefe RS; McEvoy JP; McMahon RP; Marder SR; Peterson BS; Lieberman JA
    Neuropsychopharmacology; 2013 Jun; 38(7):1245-52. PubMed ID: 23325325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
    Haig G; Wang D; Othman AA; Zhao J
    Neuropsychopharmacology; 2016 Nov; 41(12):2893-2902. PubMed ID: 27319970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
    Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
    Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
    Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
    Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
    Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
    Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia.
    Pietrzak RH; Olver J; Norman T; Piskulic D; Maruff P; Snyder PJ
    J Clin Exp Neuropsychol; 2009 Oct; 31(7):848-59. PubMed ID: 19142774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
    Umbricht D; Keefe RS; Murray S; Lowe DA; Porter R; Garibaldi G; Santarelli L
    Neuropsychopharmacology; 2014 Jun; 39(7):1568-77. PubMed ID: 24549101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW; Keefe RS; Lieberman JA; Barch DM; Csernansky JG; Goff DC; Gold JM; Green MF; Jarskog LF; Javitt DC; Kimhy D; Kraus MS; McEvoy JP; Mesholam-Gately RI; Seidman LJ; Ball MP; McMahon RP; Kern RS; Robinson J; Marder SR
    Biol Psychiatry; 2011 Mar; 69(5):442-9. PubMed ID: 21145041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia.
    Burton CZ; Vella L; Harvey PD; Patterson TL; Heaton RK; Twamley EW
    Schizophr Res; 2013 May; 146(1-3):244-8. PubMed ID: 23507359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia.
    Turner DC; Clark L; Pomarol-Clotet E; McKenna P; Robbins TW; Sahakian BJ
    Neuropsychopharmacology; 2004 Jul; 29(7):1363-73. PubMed ID: 15085092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study.
    Olivier MR; Killian S; Chiliza B; Asmal L; Schoeman R; Oosthuizen PP; Kidd M; Emsley R
    Psychol Med; 2015 Oct; 45(13):2873-83. PubMed ID: 25998030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 10-minute measure of global cognition: Validation of the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS).
    Hurford IM; Ventura J; Marder SR; Reise SP; Bilder RM
    Schizophr Res; 2018 May; 195():327-333. PubMed ID: 28918221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
    Brown D; Nakagome K; Cordes J; Brenner R; Gründer G; Keefe RSE; Riesenberg R; Walling DP; Daniels K; Wang L; McGinniss J; Sand M
    Schizophr Bull; 2019 Mar; 45(2):350-359. PubMed ID: 29718385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Brazilian standardization of the MATRICS consensus cognitive battery (MCCB): Psychometric study.
    Fonseca AO; Berberian AA; de Meneses-Gaya C; Gadelha A; Vicente MO; Nuechterlein KH; Bressan RA; Lacerda ALT
    Schizophr Res; 2017 Jul; 185():148-153. PubMed ID: 28110814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.
    Marx CE; Lee J; Subramaniam M; Rapisarda A; Bautista DC; Chan E; Kilts JD; Buchanan RW; Wai EP; Verma S; Sim K; Hariram J; Jacob R; Keefe RS; Chong SA
    Psychopharmacology (Berl); 2014 Sep; 231(17):3647-62. PubMed ID: 25030803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.